GSK is on track to achieve its guidance for 2024, with its Q3 2024 and 9m 2024 results today. Explore more details here.

GSK reports Q3 sales of $10.42 billion, missing estimates due to an 18% drop in vaccine revenue, while specialty medicines ...

This writer thinks GSK shares appear very cheap after the Q3 results, making him wonder if now's the time for him to invest ...

GSK plc (LON:GSK – Get Free Report) insider Jonathan Symonds bought 7,150 shares of the stock in a transaction dated ...

Shares of GlaxoSmithKline (GSK) Pharmaceuticals surged up to 3.4 per cent at Rs 2719.90 per share on the BSE in Wednesday’s ...

GSK plc GSK reported third-quarter 2024 core ... The upside was partially offset by the removal of the Average Manufacturer Price cap on Medicaid drug prices in the United States, adversely ...

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.50 ... corporate insider sentiment is positive on ...

GSK said it acquired an experimental therapy from Chimagen Biosciences that it aims to test in different forms of lupus, and ...

In a report released today, Jo Walton from UBS maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target ...

In the third quarter, GSK saw weaker-than-expected sales for its respiratory syncytial virus (RSV) and shingles vaccines.

The firm has removed its price target for GSK, previously set to guide investors on the stock's potential value. The downgrade reflects concerns about the limited upside in the company's pipeline ...

Price Action: At last check on Wednesday, GSK stock was down 4.69% to $36.38 during the premarket session. "ACTIVE INVESTORS' SECRET WEAPON" Supercharge Your Stock Market Game with the #1 "news ...